Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Taiwanese (TAIEX) Pharma Industry Analysis

UpdatedFeb 26, 2026
DataAggregated Company Financials
Companies59
  • 7D0.5%
  • 3M-2.5%
  • 1Y4.3%
  • YTD2.5%

Over the last 7 days, the Pharma industry has risen 1.6%, and Bora Pharmaceuticals contributed the most with a gain of 4.1%. Meanwhile, Alar Pharmaceuticals actually underperformed within the industry, shrinking 16% in the last week. In the last 12 months, the industry was up 6.7%. Earnings are forecast to grow by 88% annually.

Industry Valuation and Performance

Has the Taiwanese Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 26 Feb 2026NT$759.3bNT$119.3bNT$12.4b17x61.2x6.4x
Sat, 24 Jan 2026NT$800.6bNT$119.3bNT$12.4b17.5x64.5x6.7x
Mon, 22 Dec 2025NT$747.3bNT$118.0bNT$12.3b16.7x60.8x6.3x
Wed, 19 Nov 2025NT$676.6bNT$117.4bNT$12.4b16.1x54.7x5.8x
Fri, 17 Oct 2025NT$794.3bNT$118.3bNT$9.6b15.8x82.6x6.7x
Sun, 14 Sep 2025NT$842.2bNT$118.4bNT$10.2b16.5x82.4x7.1x
Tue, 12 Aug 2025NT$690.2bNT$117.5bNT$12.5b17.3x55.4x5.9x
Thu, 10 Jul 2025NT$630.7bNT$116.0bNT$14.3b18.5x44.1x5.4x
Sat, 07 Jun 2025NT$631.0bNT$115.9bNT$14.3b19.1x44.2x5.4x
Mon, 05 May 2025NT$566.9bNT$113.3bNT$10.6b18.9x53.5x5x
Wed, 02 Apr 2025NT$588.8bNT$112.8bNT$10.8b18.3x54.4x5.2x
Fri, 28 Feb 2025NT$674.8bNT$109.4bNT$11.5b23.5x58.7x6.2x
Sun, 26 Jan 2025NT$612.0bNT$109.3bNT$11.4b21.7x53.5x5.6x
Tue, 24 Dec 2024NT$591.2bNT$109.3bNT$11.4b21.7x51.7x5.4x
Thu, 21 Nov 2024NT$632.2bNT$109.1bNT$11.5b23x55.1x5.8x
Sat, 19 Oct 2024NT$622.7bNT$104.7bNT$8.9b27x69.6x5.9x
Mon, 16 Sep 2024NT$630.8bNT$104.7bNT$8.9b25.1x70.5x6x
Wed, 14 Aug 2024NT$640.0bNT$101.4bNT$7.3b28.7x87.3x6.3x
Fri, 12 Jul 2024NT$681.6bNT$100.5bNT$6.8b31.8x99.8x6.8x
Sun, 09 Jun 2024NT$636.7bNT$100.4bNT$7.1b29.7x89.1x6.3x
Tue, 07 May 2024NT$618.1bNT$101.8bNT$9.3b25.1x66.1x6.1x
Thu, 04 Apr 2024NT$696.9bNT$101.5bNT$9.4b26.7x74.5x6.9x
Sat, 02 Mar 2024NT$657.1bNT$101.7bNT$8.3b23.6x79.5x6.5x
Mon, 29 Jan 2024NT$590.5bNT$101.9bNT$7.8b23.7x75.8x5.8x
Wed, 27 Dec 2023NT$576.9bNT$101.6bNT$7.6b23.5x75.6x5.7x
Fri, 24 Nov 2023NT$567.4bNT$101.6bNT$8.3b23.6x68.5x5.6x
Sun, 22 Oct 2023NT$521.7bNT$101.7bNT$9.6b20.2x54.2x5.1x
Tue, 19 Sep 2023NT$564.3bNT$101.7bNT$9.6b22.5x58.6x5.6x
Thu, 17 Aug 2023NT$546.0bNT$101.1bNT$9.1b20.6x60.3x5.4x
Sat, 15 Jul 2023NT$569.2bNT$98.7bNT$10.1b16.9x56.6x5.8x
Mon, 12 Jun 2023NT$588.0bNT$98.6bNT$10.1b17x58.5x6x
Wed, 10 May 2023NT$571.5bNT$92.1bNT$8.6b21.5x66.6x6.2x
Fri, 07 Apr 2023NT$582.4bNT$91.5bNT$8.7b20.8x67.3x6.4x
Sun, 05 Mar 2023NT$562.2bNT$84.7bNT$7.6b23.5x73.7x6.6x
Price to Earnings Ratio

73.7x


Total Market Cap: NT$562.2bTotal Earnings: NT$7.6bTotal Revenue: NT$84.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Taiwanese Pharma Industry Price to Earnings3Y Average 65.8x202420252026
Current Industry PE
  • Investors are pessimistic on the Taiwanese Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 61.8x which is lower than its 3-year average PE of 65.8x.
  • The industry is trading close to its 3-year average PS ratio of 6.0x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 18% per year over the last three years.
  • Revenues for these companies have grown 12% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Taiwanese Healthcare industry?

TW Market5.35%
Healthcare2.01%
Pharma0.54%
Pharma0.54%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
6919 Caliway BiopharmaceuticalsNT$162.501.6%
+NT$3.9b		73.2%PS7198.5x
4123 Center LaboratoriesNT$43.909.8%
+NT$2.9b		11.5%PE18.4x
6472 Bora PharmaceuticalsNT$502.002.4%
+NT$1.5b		-33.1%PE14.7x
6620 Handa PharmaceuticalsNT$80.607.5%
+NT$881.0m		-12.3%PE18.6x
1720 Standard Chemical & PharmaceuticalNT$65.407.7%
+NT$839.9m		4.1%PE13.1x

Latest News

1720
NT$65.40
Standard Chemical & Pharmaceutical
7D
7.7%
1Y
4.1%
6919
NT$162.50
Caliway Biopharmaceuticals
7D
1.6%
1Y
73.2%
6535
NT$173.50
Lumosa Therapeutics
7D
-3.1%
1Y
-23.7%
6634
NT$36.60
Sinew Pharma
7D
-6.2%
1Y
-29.9%
1795
NT$279.00
Lotus Pharmaceutical
7D
-4.6%
1Y
1.6%

1795: Korea Presbyopia Filing And Regional Rights Will Support Future Upside

Analysts have kept their NT$415.8 price target for Lotus Pharmaceutical unchanged, citing minimal tweaks to the discount rate and implied future P/E assumptions rather than any shift in their core views on revenue growth or margins. What's in the News Lotus Pharmaceutical and LENZ Therapeutics reported that Lotus has submitted a New Drug Application to the Ministry of Food and Drug Safety in South Korea for VIZZTM, a treatment for presbyopia in adults (Key Developments).
6576
NT$83.30
Foresee Pharmaceuticals
7D
-1.5%
1Y
-2.5%
6472
NT$502.00
Bora Pharmaceuticals
7D
2.4%
1Y
-33.1%

6472: Corealis Alliance Will Support Future Upside Through End To End Development

Analysts have modestly adjusted their price target on Bora Pharmaceuticals to reflect updated assumptions around discount rate, revenue growth, profit margin and future P/E. This has resulted in a refreshed fair value estimate of about NT$741.02 per share.
1789
NT$21.35
ScinoPharm Taiwan
7D
-1.4%
1Y
-7.6%
6620
NT$80.60
Handa Pharmaceuticals
7D
7.5%
1Y
-12.3%
7829
NT$54.70
Yoda Pharmaceuticals
7D
-6.8%
1Y
n/a
4743
NT$59.60
Oneness Biotech
7D
2.4%
1Y
-23.5%
6785
NT$219.00
Alar Pharmaceuticals
7D
-18.1%
1Y
47.0%
7754
NT$59.80
AnnJi Pharmaceutical
7D
15.0%
1Y
99.7%
4123
NT$43.90
Center Laboratories
7D
9.8%
1Y
11.5%
6586
NT$25.65
CHO Pharma
7D
-2.8%
1Y
-58.4%